• Explore /
  • Poster
  • / A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.

A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.

Abstract Video & Slides Poster

Authors

null

Els Van Nieuwenhuysen

Leuven Cancer Institute, Leuven, Belgium

Els Van Nieuwenhuysen , Sara Bouberhan , Konstantinos Papadimitriou , Rebecca Christian Arend , Jung-Yun Lee , Roisin Eilish O'Cearbhaill , David M. O'Malley , Benoit You , Antonio Gonzalez Martin , Judith Michels , Linda R. Mileshkin , Yeh Chen Lee , Rowan Miller , Suk-Young Yoo , Mary Jane Peterman , Tamara Schmidt , David Knorr , Israel Lowy , Thomas S. Uldrick , Elizabeth Miller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03564340

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS5632)

DOI

10.1200/JCO.2024.42.16_suppl.TPS5632

Abstract #

TPS5632

Poster Bd #

497b

Abstract Disclosures

Similar Posters

First Author: Drew W. Rasco

First Author: Alan Loh Ho

First Author: B.J. Rimel

First Author: Jessica Dreger McDermott